BIOTECH
Cipla makes additional investment in German mRNA biotech
Ethris' has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary ciliary dyskinesia - a rare yet chronic respiratory disease. During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.
Ajooni Biotech ties up with Avalon Bioenergy for sustainable moringa processing
Ajooni Biotech has partnered with Avalon Bioenergy, an Indian subsidiary of the US-based Avalon Energy Group, to establish processing plants for the sustainable processing of moringa seeds and leaves in India. Avalon will extract oil for further processing and marketing, while Ajooni will use the remaining oil cake to create animal feed products for further processing and distribution within India and for exports.
Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiary
Lupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development and Manufacturing Organization (CDMO) business. Abdelaziz Toumi (Abdel), with extensive experience in biotech, pharma, and CDMO sectors across multiple continents, has been appointed as the CEO of LMS.
Lupin appoints Abdelaziz Toumi as CEO of newly formed arm
Lupin Ltd appointed Abdelaziz Toumi as CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). Toumi, with over 20 years in biotech, pharma, and CDMO sectors, has held roles at Bayer, Merck, and Lonza. Based in Switzerland, he will also focus on India. LMS specializes in APIs and CDMO services.
Bharat Bio's Rotavirus vaccine Rotavac may be unsafe for children: Study
A study found that Bharat Biotech's Rotavac vaccine used in the government's immunization program increases the risk of intussusception in infants, a condition where the intestine telescopes into itself, leading to potential serious consequences.
Ajanta Pharma buyback: Last day today to buy shares for Rs 285 crore special situation opportunity
Ajanta Pharma has set May 30 as the record date for its Rs 285 crore share buyback,. The buyback, at a premium of 12.6%, targets 10,28,881 equity shares, constituting 8.34% of the company's aggregate equity. Amidst strong financials, the company reported a 66% YoY growth in PAT and a 20% YoY increase in revenue in its Q4 results.
Concord Biotech stock slips over 5% after Rs 519 crore worth of shares change hands
Shares of Concord Biotech fell 5.3% on BSE due to a large block deal where Ontario Inc. sold a 3.4% stake at a discount, impacting stock performance.
Q4 results today: ITC, IndiGo among 181 companies to announce earnings on Thursday
181 companies, including IndiGo and ITC, will announce their quarterly earnings for Jan-Mar 2024. IndiGo is expected to post healthy earnings, while ITC may see muted revenue growth.
Alvotech, Dr. Reddy's ink pact for commercialisation of denosumab
Alvotech and Dr. Reddy's partner for AVT03, a biosimilar to Prolia and Xgeva, treating osteoporosis and skeletal-related events. The agreement includes exclusive US commercialization rights.
Ajooni Biotech offers rights issue to raise Rs 44 crore
Funds raised through the issue will be utilised to finance expenditure towards acquisition of land, site development and civil work, to acquire plant and machinery, part finance working capital requirement and corporate purposes, the company said.
ICMR distances itself from BHU's Covaxin study, asks to explain why it should not seek Iegal and administrative action
The Indian Council of Medical Research (ICMR) has criticised Banaras Hindu University (BHU) researchers for incorrectly associating them with an observational study on the side effects of Bharat Biotech's Covid-19 vaccine, Covaxin. The study, which covered a one-year period after the vaccine was administered, found that nearly a third of the 926 participants reported adverse events of special interest (AESI).
Stocks in news: ZEE, Delhivery, Bandhan Bank, JSW Steel, Concord Biotech
ZEE Ltd has reported a net profit of Rs 13.35 crore for the quarter ended March 2024, compared with a loss of Rs 196 crore in the same quarter of last year.
Covaxin demonstrated excellent safety record during studies: Bharat Biotech
Bharat Biotech asserted the safety of its Covid-19 vaccine, Covaxin, citing various studies published in peer-reviewed journals. This statement followed a report in The Economic Times regarding adverse events of special interest (AESI) reported by participants in an observational study on Covaxin. The company emphasized the need for comprehensive safety data in such studies, including comparisons with non-vaccinated subjects and those receiving other vaccines.
Covaxin side effects: What are the symptoms reported in adverse event cases? Should you worry?
Covaxin side effects: A recent study highlighted adverse events post-Bharat Biotech's Covaxin vaccinations. Led by Sankha Shubhra Chakrabarti, it noted higher risk in female adolescents and those with allergies. Of 1,024 participants, 47.9% adolescents and 42.6% adults reported viral infections. Common AESIs included skin disorders, menstrual abnormalities in females, and serious cases like stroke. Monitoring vaccinated individuals, especially those with prior Covid history, is crucial.
Adverse events seen in some participants who took Covaxin, reports new study
Covaxin Vaccine Side Effects: In an observational study on Bharat Biotech's Covaxin, nearly a third of participants reported adverse events of special interest (AESI), with females and those with allergies at higher risk. The majority of AESIs persisted at the 1-year follow-up. Common AESIs included viral upper respiratory tract infections, skin disorders, and nervous system issues. Serious AESIs like stroke and Guillain-Barre Syndrome were rare but reported. Females, adolescents, and those with pre-vaccination Covid-19 or comorbidities had higher odds of AESIs. Extended surveillance is recommended to understand late-onset adverse events.
In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
Nandini Piramal projects early teens revenue growth for FY25 and 22-25% EBITDA growth margins in 3-5 years. Revenue increase drives margin expansion through cost optimization and operational excellence, with a focus on CDMO and Indian consumer products growth.
Bharat Biotech says its Covaxin demonstrated ‘excellent safety records’
Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry.
Stocks in news: Ultratech, IOC, Adani Energy, Adani Total Gas, Kfin Tech, Tata Chemicals
Spandana Sphoorty reported consolidated net profit of Rs 122 crore for the quarter ended March 2024. The net interest income jumped 21% year-on-year.
Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines production, supply
Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement.
Load More
